Drug Discovery

Drug-Target Prioritization Before the Next Validation Cycle

Published 2026-08-22 · Updated 2026-08-22

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which target deserves the next validation budget

Why the problem is difficult

The article-specific identification challenge is whether the question “which target deserves the next validation budget” can be resolved using human genetics, disease biology, expression, tractability, safety, competitive landscape, and translational evidence, rather than merely restated in new language.

A falsifier-first workflow

• Define the decision precisely: which target deserves the next validation budget.
• Build a source and data ledger around human genetics, disease biology, expression, tractability, safety, competitive landscape, and translational evidence.
• Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
• Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
• Run the lowest-cost discriminating challenge: remove the strongest evidence source and test whether the target remains top-ranked.
• Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

• Decision impact: would the result materially change the choice about which target deserves the next validation budget?
• Evidence fit: does the available evidence—human genetics, disease biology, expression, tractability, safety, competitive landscape, and translational evidence—directly address the decision rather than merely correlate with it?
• Discrimination: does the preferred route predict an outcome a credible alternative does not?
• Robustness: does the ranking survive the challenge “remove the strongest evidence source and test whether the target remains top-ranked”?
• Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

human genetics, disease biology, expression, tractability, safety, competitive landscape, and translational evidence

Counterevidence

For this decision, a result from “remove the strongest evidence source and test whether the target remains top-ranked” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which target deserves the next validation budget or exposes why the available evidence cannot resolve it.

Fastest falsifier

remove the strongest evidence source and test whether the target remains top-ranked

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “remove the strongest evidence source and test whether the target remains top-ranked” without an independently supported alternative mechanism.

Evidence ceiling

A computational ranking does not validate a target or predict clinical success.

Sources and starting points

• Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
• ChEMBL — Curated bioactivity information for compounds, assays, and targets.
• ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
• PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
• AlphaFold Protein Structure Database — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
• Europe PMC — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

1. Target Identification vs Target Validation in Drug Discovery
2. What Counts as Evidence for Drug Target Validation?
3. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Drug Target Prioritization: A Falsifier-First Framework” help make?

It supports a bounded decision about which target deserves the next validation budget. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.

What is the fastest useful test?

remove the strongest evidence source and test whether the target remains top-ranked

Can computation validate the final scientific claim?

No. A computational ranking does not validate a target or predict clinical success. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.